Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk (NYSE: NVO ) is one of the stocks that should double in 3 years . On February 4, Novo Nordisk delivered 10% sales growth in 2025, driven by its obesity and diabetes portfolios. The company's obesity care sales reached DKK 82 billion, marking a substantial increase since 2019 and expanding its reach to 16 million additional patients. Financial results surpassed expectations with a reported EPS of $1, although the gross margin decreased to 81% due to manufacturing acquisitions and restructuring costs. The year was highlighted by major regulatory and pipeline milestones, including the FDA approval and successful launch of the Wegovy pill, the first oral GLP-1 for weight management. Clinical data for CagriSema showed superior weight loss and glycemic control compared to semaglutide, and the company is progressing with its next-gen treatment, zenagamtide. Additionally, Novo Nordisk is expanding its focus into rare diseases and cardiovascular comorbidities, with several Phas
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Reframing The Novo Nordisk (CPSE:NOVO B) Narrative As Analysts Reset Expectations And Valuation [Yahoo! Finance]Yahoo! Finance
- Drugmaker Aspen plans Africa weight-loss drug push [Yahoo! Finance]Yahoo! Finance
- CagriSema Incident: The Surprise Winner And What It Means For The Novo-Lilly Rivalry [Seeking Alpha]Seeking Alpha
- Study Says Ozempic Knockoffs Could Cost $3 [Yahoo! Finance]Yahoo! Finance
- Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics' [CNBC]CNBC
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/2/26 - Form 6-K
- 3/2/26 - Form 6-K
- 2/23/26 - Form 6-K
- NVO's page on the SEC website